The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay

Journal of Clinical Microbiology

Volumn 50, Issue 11, 2012, Pages 3712-3716

  Barnard, M ^a,b   Gey Van Pittius, N C ^b   Van Helden, P D ^b   Bosman, M ^a   Coetzee, G ^a   Warren, R M ^b  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; LABORATORY; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 84867506400     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01958-12     Document Type: Article

References (31)

1. Al-Zamel FA. 2009. Detection and diagnosis of Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 7:1099-1108.
2. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N. 2011. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J. Clin. Microbiol. 49:1772-1776.
3. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. 2008. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177:787-792. (Pubitemid 351490566)
4. Blakemore R, et al. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J. Clin. Microbiol. 48:2495-2501.
5. Boehme CC, et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015.
6. Bwanga F, Hoffner S, Haile M, Joloba ML. 2009. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect. Dis. 9:67. doi:10.1186/1471-2334-9-67.
7. Cattamanchi A, et al. 2009. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect. Dis. 9:53. doi:10.1186/1471-2334-9-53.
8. Crudu V, et al. 2012. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J. Clin. Microbiol. 50:1264-1269.
9. Davies GR. 2010. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. Tuberculosis (Edinb.) 90:171-176.
10. Foundation for Innovative New Diagnostics. 2009. Drug resistant TB and new diagnostics for people living with HIV: emerging results from FIND 2009. Foundation for Innovative New Diagnostics, Geneva, Switzerland. www.stoptb.org/wg/tb-hiv/assets/documents/DRUGRE~1.PDF. Accessed 26 May 2011.
11. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. 2011. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J. Clin. Microbiol. 49:1202-1205.
12. Ichiyama S, Suzuki K. 2005. Clinical application of testing methods on acid-fast bacteria. Kekkaku 80:95-111. (In Japanese.) (Pubitemid 40637215)
13. Kaul KL. 2001. Molecular detection of Mycobacterium tuberculosis: impact on patient care. Clin. Chem. 47:1553-1558. (Pubitemid 32678851)
14. Kent PT, Kubica GP. 1985. Public health mycobacteriology, a guide for the level III laboratory, publication no 86-216546. CDC, Atlanta, GA.
15. Marahatta SB. 2010. Multi-drug resistant tuberculosis burden and risk factors: an update. Kathmandu Univ. Med. J. 8:116-125.
16. Marais BJ, et al. 2008. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin. Infect. Dis. 47:203-207. (Pubitemid 351920621)
17. Miller MB, Popowitch EB, Backlund MG, Ager EP. 2011. Performance of Xpert MTB/RIF RUO assay and IS6110 real-time PCR for Mycobacterium tuberculosis detection in clinical samples. J. Clin. Microbiol. 49: 3458-3462.
18. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. 2012. Early tuberculosis treatment monitoring by Xpert MTB/RIF. Eur. Respir. J. 39: 1269-1271.
19. Rachow A, et al. 2011. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay - a clinical validation study. PLoS One 6 : e20458. doi:10.1371/journal-.pone.0020458.
20. Richter E, Rusch-Gerdes S, Hillemann D. 2009. Drug-susceptibility testing in TB: current status and future prospects. Expert Rev. Respir. Med. 3:497-510.
21. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. 2012. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int. J. Tuberc. Lung Dis. 16:203-205.
22. Sreeramareddy CT, Panduru KV, Menten J, Van den EJ. 2009. Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect. Dis. 9:91. doi:10.1186/1471-2334-9-91.
23. Steingart KR, et al. 2006. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect. Dis. 6:570-581. (Pubitemid 44262344)
24. Theron G, et al. 2011. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am. J. Respir. Crit. Care Med. 184:132-140.
25. Van Rie A, et al. 2012. False-positive rifampicin resistance on Xpert MTB/RIF: case report and clinical implications. Int. J. Tuberc. Lung Dis. 16:206-208.
26. Warren RM, et al. 2009. The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis (Edinb.) 89:199-202.
27. World Health Organization. 2011. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how to' practical considerations. World Health Organization, Geneva, Switzerland.http://whqlibdoc. who.int/publications/2011/9789241501569-eng.pdf. Accessed 13 January 2012.
28. World Health Organization. 2009. Global tuberculosis control 2009. World Health Organization, Geneva, Switzerland. www.who.int/tb/publications/global- report/2009/en/index.html Accessed 8 August 2011.
29. World Health Organization. 2011. Global tuberculosis control 2011. World Health Organization, Geneva, Switzerland. www.whqlibdoc.who.int/publications/ 2011/9789241564380-eng.pdf Accessed 1 December 2011.
30. World Health Organization. 2010. Global tuberculosis control 2010. World Health Organization, Geneva, Switzerland. http://who.int.tb.publications/global- report/2010/en/index.html Accessed 14 September 2011.
31. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDRTB). World Health Organization, Geneva, Switzerland.http://www.who.int/tb/features- archive/policy-statement.pdf. Accessed 27 December 2009.